Stock analysts at Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report issued to clients and investors on Tuesday. The firm set a “neutral” rating on the stock.

TEVA has been the topic of several other reports. Credit Suisse Group reiterated an “underperform” rating and set a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Royal Bank of Canada dropped their target price on Teva Pharmaceutical Industries from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, September 18th. Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, October 5th. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Sunday, November 12th. Finally, BTIG Research set a $16.00 price objective on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Tuesday, November 28th. Seven research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $21.65.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $16.44 on Tuesday. The company has a market capitalization of $16,316.96, a PE ratio of 3.71 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $38.31.

A number of large investors have recently added to or reduced their stakes in the stock. Fieldpoint Private Securities LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $171,000. Arthur Zaske & Associates LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $372,000. Sterling Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $263,000. Point72 Asset Management L.P. acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $2,200,000. Finally, Chevy Chase Trust Holdings Inc. boosted its position in Teva Pharmaceutical Industries by 81.5% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after purchasing an additional 5,497 shares during the period. Institutional investors and hedge funds own 52.05% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries (TEVA) Now Covered by Analysts at Guggenheim” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-now-covered-by-analysts-at-guggenheim/1759041.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.